3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
26
Gastrointestinal
5
Thoracic
3
CNS
3
Breast
3
Other hematologic neoplasm
2
Lymphoid
2
Gynecologic
2
Genitourinary
2
Other solid neoplasm
1
NET
1
Endocrine
1
Dermatologic
1
Conditions
Melanoma
5
Lymphoma, Large B-Cell, Diffuse
4
Burkitt Lymphoma
4
Sezary Syndrome
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Intraocular Lymphoma
3
Immunoblastic Lymphadenopathy
3
Hodgkin Disease
3
Ovarian Neoplasms
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Interventions
Cyclophosphamide
16
pembrolizumab
14
Radiosurgery
7
Nivolumab
5
Celecoxib
5
poly ICLC
4
Radiation
4
Injections
4
Radiotherapy
3
Melphalan
3
Ipilimumab
3
Filgrastim
3
Etoposide
3
Docetaxel
3
Cryosurgery
3
Blood Specimen Collection
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Transurethral Resection of Prostate
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Irinotecan
×
Dermatologic
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts